Role of anti-CD20 monoclonal antibody in association with immunomodulatory agents

被引：2

作者：

Bosly, A ^{[1
]}

机构：

[1] Clin Univ UCL Mont Godinne, Hematol Serv, B-5530 Yvoir, Belgium

来源：

PATHOLOGIE BIOLOGIE | 2004年 / 52卷 / 01期

关键词：

rituximab; immunomodulators agents; indolent lymphjomas; immunotherapy; interferon;

D O I：

10.1016/S0369-8114(03)00051-8

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Chimeric monoclonal anti-CD20 antibody (Rituximab) has been associated with immunomodulatory agents such as interferon alpha, interleukin-2, interleukin-12, G-CSF, GM-CSF and anti-CD22 humanized monoclonal antibody (Epratuzumab). Synergy with interferon is clearly demonstrated increasing complete response rate and response duration. Other associations are promising but must be tested in randomized prospective trials versus rituximab alone, probably in indolent lymphomas where chemotherapy could be avoided. (C) 2003 Elsevier SAS. Tous droits reserves.

引用

页码：39 / 42

页数：4

共 19 条

[1]

ABBAS AK, 2000, CELL MOL IMMUNOLOGY

[2] Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma [J].

Ansell, SM ;

Witzig, TE ;

Kurtin, PJ ;

Sloan, JA ;

Jelinek, DF ;

Howell, KG ;

Markovic, SN ;

Habermann, TM ;

Klee, GG ;

Atherton, PJ ;

Erlichman, C .

BLOOD, 2002, 99 (01) :67-74

[3]

Bosly A., 2001, Experimental Hematology (Charlottesville), V29, P72

[4]

BOSLY A, 1992, EXP HEMATOL, V20, P962

[5] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[6] Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden:: clinical and molecular evaluation [J].

Colombat, P ;

Salles, G ;

Brousse, N ;

Eftekhari, P ;

Soubeyran, P ;

Delwail, V ;

Deconinck, E ;

Haïoun, C ;

Foussard, C ;

Sebban, C ;

Stamatoullas, A ;

Milpied, N ;

Boué, F ;

Taillan, B ;

Lederlin, P ;

Najman, A ;

Thièblemont, C ;

Montestruc, F ;

Mathieu-Boué, A ;

Benzohra, A ;

Solal-Céligny, P .

BLOOD, 2001, 97 (01) :101-106

[7] Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy [J].

Czuczman, MS ;

Grillo-López, AJ ;

White, CA ;

Saleh, M ;

Gordon, L ;

LoBuglio, AF ;

Jonas, C ;

Klippenstein, D ;

Dallaire, B ;

Varns, C .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :268-276

[8]

Davis TA, 2000, CLIN CANCER RES, V6, P2644

[9] Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma [J].

Friedberg, JW ;

Neuberg, D ;

Gribben, JG ;

Fisher, DC ;

Canning, C ;

Koval, M ;

Poor, CM ;

Green, LM ;

Daley, J ;

Soiffer, R ;

Ritz, J ;

Freedman, AS .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (04) :828-834

[10]

GISSELBRECHT C, 1994, BLOOD, V83, P2081

← 1 2 →